PR87566

MONTREAL, Jan. 13, 2021 /PRNewswire=KYODO JBN/ --

Caprion-HistoGeneX, a leading global contract research laboratory services

provider backed by Arsenal Capital Partners ("Arsenal"), announced today the

acquisition of Mosaic Laboratories LLC ("Mosaic"), a California-based company

offering histology and immunohistochemistry services to global pharmaceutical

clients. The addition of Mosaic further strengthens the North American base for

Caprion-HistoGeneX's histopathology assay development and deployment, expands

the volume of pathology services and consolidates the company's position as a

world-leading service provider of histopathology biomarker analysis for global

clinical trials.

Logo -

https://mma.prnewswire.com/media/1418425/Caprion_Biosciences_Caprion_HistoGeneX_Expands_its_Histological.jpg

Logo -

https://mma.prnewswire.com/media/1418571/Caprion_Biosciences_Caprion_HistoGeneX_Expands_its_Histological.jpg

Mosaic is a pioneer in using multiplex immunohistochemistry with spectral

imaging and is recognized for its outstanding services for the development,

validation and implementation of complex immunohistochemistry, in situ

hybridization and FISH assays, positioning itself as one of the most prominent

and comprehensive providers in the field. Core Mosaic capabilities include

study design, assay development and deployment, data interpretation, and

services to support exploratory biomarker analysis at pre-clinical and clinical

trial stages, thereby enabling timely decisions for patient selection.

"We are truly excited to join forces with Caprion-HistoGeneX. This partnership

provides strong collaboration opportunities that will further support the

programs of our clients and allow us to globalize our existing and future

assays to support clinical trials," said Chris Kerfoot and Lisa Dauffenbach,

Co-founders and Managing Members of Mosaic.

"The combination of Mosaic and Caprion-HistoGeneX strengthens our leadership

position as a global provider of precision medicine services offering the full

range of immunohistochemistry, immune monitoring, proteomics and genomics

biomarkers" said Martin LeBlanc, CEO of Caprion-HistoGeneX. "Mosaic's excellent

track record of developing and deploying complex immunohistochemistry assays

will improve our ability to meet the rapidly expanding needs of our clients for

histopathology services across our global network of laboratories in North

America, Europe, and Asia, including China."

"The addition of Mosaic reflects Arsenal's commitment to support the

development and international expansion of Caprion-HistoGeneX through continued

investment in complementary capabilities, services and geographic coverage, and

solidifies the company's leadership position in one of the fastest growing

areas of biopharma R&D." said David Spaight, the Executive Chairman of

Caprion-HistoGeneX and an Operating Partner of Arsenal.

In conjunction with this transaction and the recently announced acquisition of

Clinical Logistics Inc., Caprion-HistoGeneX is also planning to unveil in the

coming weeks its new corporate name and brand identity for the combined

entities reflecting its vision and positioning as a leading global provider of

precision medicine services.  

Kirkland & Ellis LLP acted as legal advisors to Caprion-HistoGeneX.

Intrepid Investment Bankers LLC acted as financial advisor, and Davis Wright

Tremaine LLP acted as legal advisor to Mosaic.

About Caprion-HistoGeneX  

Caprion-HistoGeneX is a leading provider of specialized precision medicine

laboratory services to the biopharmaceutical industry. Leveraging its

integrated analytical platforms in immunology, histopathology, proteomics and

genomics, as well as related specimen collection and logistics services,

Caprion-HistoGeneX supports the entire drug development cycle, from discovery

to late stage clinical trials. The company operates globally with 9 facilities

located in Canada, USA, Belgium, Australia, and China.

For more information:  www.caprion.com  and  www.histogenex.com

About Mosaic Laboratories LLC

Mosaic is a leader in providing preclinical and clinical services to the

pharmaceutical industry and has pioneered multiplex chromogenic

immunohistochemistry using multispectral imaging. Mosaic develops proprietary

assays, tissue banks, and software algorithms to support data analysis.

Leveraging this longstanding and highly differentiated multiplex IHC expertise,

Mosaic has built a reputation as having the highest-quality validated assays,

vivid multiplex IHC images, and rapid development and implementation of new

assays, backed with an uncompromising service focus on speed, agility and

customer service. The company has also developed a broader menu of central lab

services, including histology, FISH, and ISH.

For more information: https://www.mosaiclabs.com

About Arsenal Capital Partners

Arsenal is a leading private equity firm that specializes in investments in

middle-market healthcare and industrials companies.  Since its inception in

2000, Arsenal has raised institutional equity investment funds of $5.3 billion,

has completed more than 200 platform and add-on investments, and achieved more

than 30 realizations. Arsenal invests in industry sectors in which the firm has

significant prior knowledge and experience. The firm works with management

teams to build strategically important companies with leading market positions,

high growth and high value-add.

For more information: www.arsenalcapital.com.

CONTACT: Caprion-HistoGeneX : Guylaine Galipeau, Global Marketing Director,

Caprion-HistoGeneX, ggalipeau@caprion.com ; Arsenal Capital Partners: Prosek

Partners, Brian Schaffer / Kristen Duarte, bschaffer@prosek.com /

kduarte@prosek.com

Source - Caprion Biosciences Inc.